HK1037865A1 - Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells. - Google Patents

Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells.

Info

Publication number
HK1037865A1
HK1037865A1 HK01107620A HK01107620A HK1037865A1 HK 1037865 A1 HK1037865 A1 HK 1037865A1 HK 01107620 A HK01107620 A HK 01107620A HK 01107620 A HK01107620 A HK 01107620A HK 1037865 A1 HK1037865 A1 HK 1037865A1
Authority
HK
Hong Kong
Prior art keywords
cells
ischaemia
rosiglitazone
reducing
glucose uptake
Prior art date
Application number
HK01107620A
Other languages
English (en)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Glaxosmithkline S A S Smithkli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Glaxosmithkline S A S Smithkli filed Critical Glaxosmithkline S A S Smithkli
Publication of HK1037865A1 publication Critical patent/HK1037865A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK01107620A 1998-07-21 2001-10-31 Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells. HK1037865A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
HK1037865A1 true HK1037865A1 (en) 2002-02-22

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107620A HK1037865A1 (en) 1998-07-21 2001-10-31 Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells.

Country Status (26)

Country Link
EP (2) EP1098639B1 (tr)
JP (1) JP2002521326A (tr)
KR (1) KR20010079551A (tr)
CN (1) CN1310620A (tr)
AP (1) AP2001002036A0 (tr)
AT (1) ATE288746T1 (tr)
AU (1) AU5053799A (tr)
BG (1) BG105250A (tr)
BR (1) BR9912117A (tr)
CA (1) CA2338211A1 (tr)
DE (1) DE69923687T2 (tr)
DK (1) DK1098639T3 (tr)
EA (1) EA200100165A1 (tr)
ES (1) ES2237929T3 (tr)
HK (1) HK1037865A1 (tr)
HU (1) HUP0103199A3 (tr)
ID (1) ID26986A (tr)
IL (1) IL140664A0 (tr)
NO (1) NO20010292L (tr)
OA (1) OA11579A (tr)
PL (1) PL345627A1 (tr)
PT (1) PT1098639E (tr)
SI (1) SI1098639T1 (tr)
SK (1) SK1012001A3 (tr)
TR (1) TR200100207T2 (tr)
WO (1) WO2000004890A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
CA2311125C (en) * 1997-11-19 2011-01-18 Takeda Chemical Industries, Ltd. Apoptosis inhibitor
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
BR9912117A (pt) 2001-04-10
NO20010292D0 (no) 2001-01-18
EP1516617A2 (en) 2005-03-23
OA11579A (en) 2004-06-01
EP1098639B1 (en) 2005-02-09
ES2237929T3 (es) 2005-08-01
AU5053799A (en) 2000-02-14
NO20010292L (no) 2001-03-08
ATE288746T1 (de) 2005-02-15
CN1310620A (zh) 2001-08-29
ID26986A (id) 2001-02-22
WO2000004890A1 (en) 2000-02-03
PT1098639E (pt) 2005-06-30
BG105250A (en) 2001-11-30
SI1098639T1 (tr) 2005-08-31
HUP0103199A3 (en) 2002-08-28
SK1012001A3 (en) 2001-08-06
DE69923687D1 (de) 2005-03-17
TR200100207T2 (tr) 2001-05-21
PL345627A1 (en) 2002-01-02
KR20010079551A (ko) 2001-08-22
HUP0103199A2 (hu) 2002-05-29
EA200100165A1 (ru) 2001-08-27
CA2338211A1 (en) 2000-02-03
DK1098639T3 (da) 2005-06-13
EP1098639A1 (en) 2001-05-16
IL140664A0 (en) 2002-02-10
JP2002521326A (ja) 2002-07-16
AP2001002036A0 (en) 2001-03-31
DE69923687T2 (de) 2006-04-06

Similar Documents

Publication Publication Date Title
MXPA02001866A (es) Cateter de drenaje lumbar.
HK1036408A1 (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity.
HUP0103205A3 (en) Urate oxidase
HK1046139A1 (en) Glucokinase activators.
MXPA01012560A (es) Sistema absorbente unitario.
HK1047942A1 (en) Purine derivatives.
ZA200202849B (en) Purine derivatives.
HK1047111A1 (en) Purine derivatives.
HK1018788A1 (en) Antivirally active heterocyclic azahexane derivatives.
ZA992005B (en) Proton donating actives in absorbent articles.
IL124903A0 (en) An enzyme biosensor
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
EP1176202A4 (en) GLUCOSE DEHYDROGENASE
EP0654530A3 (en) The enzyme E2-F1, carrier of ubiquitin, its purification, its production, and its use.
ZA99800B (en) Benzothiadiazoles and derivatives.
ZA9811925B (en) Thiazole derivatives.
ZA976043B (en) Polyurethane/urea heat-cured and moisture-cured elastomers with improved physical properties.
ZA99847B (en) Absorbent article with breathable dual layer backsheet comprising one layer with slanted capillary apertures.
HK1039331A1 (en) Novel imidazoles with anti-inflammatory activity.
HK1037865A1 (en) Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells.
GB9906245D0 (en) Enzyme
HK1036012A1 (en) Stable mitoxantron solutions.
HK1049329A1 (en) Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors.
ZA200006632B (en) Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity.
GB9821198D0 (en) Enzyme

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090721